Cargando…
Immune checkpoint inhibitor-induced myocarditis with myasthenia gravis overlap syndrome: A case report and literature review
The therapeutic value of immune checkpoint inhibitors (ICIs) in a variety of tumors has been found and recognized, and although ICIs have improved the prognosis of many patients with advanced tumors, these drugs sometimes cause immune-related adverse events (irAEs). PATIENT CONCERNS: We report a 67-...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9750698/ https://www.ncbi.nlm.nih.gov/pubmed/36626474 http://dx.doi.org/10.1097/MD.0000000000032240 |
_version_ | 1784850313378791424 |
---|---|
author | Gao, Loulu Li, Xuemei Guo, Zhijun Tang, Lin Peng, Jieqiong Liu, Bo |
author_facet | Gao, Loulu Li, Xuemei Guo, Zhijun Tang, Lin Peng, Jieqiong Liu, Bo |
author_sort | Gao, Loulu |
collection | PubMed |
description | The therapeutic value of immune checkpoint inhibitors (ICIs) in a variety of tumors has been found and recognized, and although ICIs have improved the prognosis of many patients with advanced tumors, these drugs sometimes cause immune-related adverse events (irAEs). PATIENT CONCERNS: We report a 67-year-old woman with advanced rectal endocrine tumor. Ten days after receiving two cycles of treatment with camrelizumab combined with http://www.baidu.com/link?url=shAWG4LYTwwBcZAEb6pLb6DkDndJR2tUgOfFiWAkOf0hS-_sj2jjSLBwYaxSiHY3r6yPj31Lp2DCP-7q3w7ho5HIV46V4fbIShFyUY7Cbka sorafenib, the patient suddenly suffered from chest tightness, shortness of breath and progressive aggravation of limb weakness, the high-sensitivity cardiac troponin T (hs-cTnT) was elevated to 3015pg/mL and N-terminal pro-B-type natriuretic peptide (NT-proBNP) up to 5671pg/mL, and creatine kinase (CK) was 1419U/L. DIAGNOSIS AND INTERVENTIONS: The patient was diagnosed as immune checkpoint inhibitor-induced myocarditis with myasthenia gravis overlap syndrome. The patient was transferred to the intensive care unit (ICU) in time and given oxygen inhalation, glucocorticoids, immunoglobulin and anticholinesterase drugs, and other related treatments. OUTCOMES: After 2 weeks, the symptoms of myasthenia gravis (MG) were relieved, and the level of myocardial injury markers decreased significantly, but it was still at a high level. The patient's family refused further treatment, and the patient died soon after. LESSONS: In this paper, Through the report and follow-up analysis of this case, this paper recognizes that the early correct understanding and evaluation of this fulminant and fatal irAEs and the reasonable treatment of patients are very important for the prognosis of patients. |
format | Online Article Text |
id | pubmed-9750698 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-97506982023-01-13 Immune checkpoint inhibitor-induced myocarditis with myasthenia gravis overlap syndrome: A case report and literature review Gao, Loulu Li, Xuemei Guo, Zhijun Tang, Lin Peng, Jieqiong Liu, Bo Medicine (Baltimore) 5700 The therapeutic value of immune checkpoint inhibitors (ICIs) in a variety of tumors has been found and recognized, and although ICIs have improved the prognosis of many patients with advanced tumors, these drugs sometimes cause immune-related adverse events (irAEs). PATIENT CONCERNS: We report a 67-year-old woman with advanced rectal endocrine tumor. Ten days after receiving two cycles of treatment with camrelizumab combined with http://www.baidu.com/link?url=shAWG4LYTwwBcZAEb6pLb6DkDndJR2tUgOfFiWAkOf0hS-_sj2jjSLBwYaxSiHY3r6yPj31Lp2DCP-7q3w7ho5HIV46V4fbIShFyUY7Cbka sorafenib, the patient suddenly suffered from chest tightness, shortness of breath and progressive aggravation of limb weakness, the high-sensitivity cardiac troponin T (hs-cTnT) was elevated to 3015pg/mL and N-terminal pro-B-type natriuretic peptide (NT-proBNP) up to 5671pg/mL, and creatine kinase (CK) was 1419U/L. DIAGNOSIS AND INTERVENTIONS: The patient was diagnosed as immune checkpoint inhibitor-induced myocarditis with myasthenia gravis overlap syndrome. The patient was transferred to the intensive care unit (ICU) in time and given oxygen inhalation, glucocorticoids, immunoglobulin and anticholinesterase drugs, and other related treatments. OUTCOMES: After 2 weeks, the symptoms of myasthenia gravis (MG) were relieved, and the level of myocardial injury markers decreased significantly, but it was still at a high level. The patient's family refused further treatment, and the patient died soon after. LESSONS: In this paper, Through the report and follow-up analysis of this case, this paper recognizes that the early correct understanding and evaluation of this fulminant and fatal irAEs and the reasonable treatment of patients are very important for the prognosis of patients. Lippincott Williams & Wilkins 2022-12-09 /pmc/articles/PMC9750698/ /pubmed/36626474 http://dx.doi.org/10.1097/MD.0000000000032240 Text en Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY) (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | 5700 Gao, Loulu Li, Xuemei Guo, Zhijun Tang, Lin Peng, Jieqiong Liu, Bo Immune checkpoint inhibitor-induced myocarditis with myasthenia gravis overlap syndrome: A case report and literature review |
title | Immune checkpoint inhibitor-induced myocarditis with myasthenia gravis overlap syndrome: A case report and literature review |
title_full | Immune checkpoint inhibitor-induced myocarditis with myasthenia gravis overlap syndrome: A case report and literature review |
title_fullStr | Immune checkpoint inhibitor-induced myocarditis with myasthenia gravis overlap syndrome: A case report and literature review |
title_full_unstemmed | Immune checkpoint inhibitor-induced myocarditis with myasthenia gravis overlap syndrome: A case report and literature review |
title_short | Immune checkpoint inhibitor-induced myocarditis with myasthenia gravis overlap syndrome: A case report and literature review |
title_sort | immune checkpoint inhibitor-induced myocarditis with myasthenia gravis overlap syndrome: a case report and literature review |
topic | 5700 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9750698/ https://www.ncbi.nlm.nih.gov/pubmed/36626474 http://dx.doi.org/10.1097/MD.0000000000032240 |
work_keys_str_mv | AT gaoloulu immunecheckpointinhibitorinducedmyocarditiswithmyastheniagravisoverlapsyndromeacasereportandliteraturereview AT lixuemei immunecheckpointinhibitorinducedmyocarditiswithmyastheniagravisoverlapsyndromeacasereportandliteraturereview AT guozhijun immunecheckpointinhibitorinducedmyocarditiswithmyastheniagravisoverlapsyndromeacasereportandliteraturereview AT tanglin immunecheckpointinhibitorinducedmyocarditiswithmyastheniagravisoverlapsyndromeacasereportandliteraturereview AT pengjieqiong immunecheckpointinhibitorinducedmyocarditiswithmyastheniagravisoverlapsyndromeacasereportandliteraturereview AT liubo immunecheckpointinhibitorinducedmyocarditiswithmyastheniagravisoverlapsyndromeacasereportandliteraturereview |